Everolimus Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib - Related Studies

Everolimus Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib

This study is ongoing, but not recruiting participants.

Study NCT00410124. Last updated on July 31, 2007. Information provided by Novartis

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Metastatic Renal Cell Carcinoma

2	Additional conditions recognized in this trial
		Carcinoma
		Carcinoma, Renal Cell

3	More general conditions related to this trial
		Adenocarcinoma
		Kidney Diseases
		Kidney Neoplasms
		Neoplasms
		Neoplasms by Histologic Type
		Neoplasms by Site
		Neoplasms, Glandular and Epithelial
		Urogenital Neoplasms
		Urologic Diseases
		Urologic Neoplasms

4	Interventions listed in this trial
		everolimus

5	More general drug interventions related to this trial
		Immunologic Factors
		Immunosuppressive Agents
		Pharmacologic Actions
		Physiological Effects of Drugs

6	Sponsors listed in this trial
		Novartis